Voyager Therapeutics (NASDAQ:VYGR) Issues Earnings Results

Voyager Therapeutics (NASDAQ:VYGR) issued its quarterly earnings results on Tuesday. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24), Zacks reports. The firm had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the firm earned $1.25 earnings per share.

Voyager Therapeutics Stock Performance

VYGR stock opened at $4.06 on Thursday. Voyager Therapeutics has a 52 week low of $3.56 and a 52 week high of $10.66. The company has a market capitalization of $221.78 million, a PE ratio of 5.72 and a beta of 0.99. The company’s 50-day simple moving average is $4.95 and its 200 day simple moving average is $5.87.

Insider Transactions at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on VYGR shares. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research note on Wednesday. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, Citigroup initiated coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $15.08.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.